Yazarlar : de Vitry A, Valois A, Weinborn M et al
Yayın : Ann Dermatol Venereol.
Yayın Yılı : 2014
Pubmed Linki : http://www.ncbi.nlm.nih.gov/pubmed/24951143
Konu : Hemofili
Literatür İçeriği :
Abstract
BACKGROUND:
Acquired haemophilia A (AH) is an uncommon bleeding disorder that presents as multiple, disseminated spontaneous subcutaneous bleeds. Diagnosis may be made on the basis of prolonged activated partial thromboplastin time (aPTT). The severity of the disease is associated with the low risk of haemoglobin levels and with potential links with other diseases.
OBSERVATIONS:
Two men were hospitalized for extensive and spontaneous subcutaneous hematoma. In both cases, the International Normalized Ratio (INR) was normal, but aPTT was 3 times higher than normal. Autoantibodies against coagulation factor VIII confirmed the diagnosis of AH. The patients received immunomodulatory treatment. In one patient, diffuse large B-cell lymphoma was discovered one year after successful treatment of AH.
DISCUSSION:
AH may be revealed by areas of bruising, subutaneous haematomas mimicking erythema nodosum, and muscle pain. APTT results alone can prompt the biologist to screen for factor VIII inhibitors. Aside from the risk of fatal bleeding, in half of all cases, the prognosis is determined by associated disorders such as blood dyscrasias, solid tumours, autoimmune diseases, use of certain medicines and pregnancy. After treatment for bleeding complications, therapy focuses on restoring the coagulation time. The aim of immunomodulatory therapy is to stem production of autoantibodies against coagulation factor VIII.
CONCLUSION:
AH must be considered rapidly in order to reduce the risk of bleeding emergencies and to screen for potential related diseases.
Copyright © 2014 Elsevier Masson SAS. All rights reserved.
Sunumlar | Videolar | Olgu Tartışması |